Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique

Autoimmunity Reviews

Volumn 8, Issue 7, 2009, Pages 552-557

  Barabas, Arpad Zsigmond ^a   Cole, Chad Douglas ^b   Barabas, Arpad David ^a   Graeff, Richard Milton ^c   Lafreniere, Rene ^a   Weir, Donald Mackay ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmune anomalies; Modified vaccination technique; Prophylactic; Therapeutic; Tolerance to self

Indexed keywords

AUTOANTIGEN; DIPHTHERIA VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TISSUE ANTIGEN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DIPHTHERIA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INFECTION; MODIFIED VACCINATION TECHNIQUE; NEOPLASM; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; TECHNIQUE; VACCINATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOIMMUNE DISEASES; NEOPLASMS; SELF TOLERANCE; VACCINATION;

EID: 67349172922     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.01.014     Document Type: Review

References (40)

1. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 12 (1991) 154-159
2. Grabar P. Autoantibodies and the physiological role of immunoglobulins. Immunol Today 4 (1983) 337-340
3. Weir D.M., Pinckard R.N., Elson C.J., and Suckling D.E. Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1 (1966) 433-442
4. Barabas A.Z., Cole C.D., Barabas A.D., and Lafreniere R. Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 85 (2004) 321-334
5. Barabas A.Z., and Lafreniere R. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 4 (2005) 565-570
6. Barabas A.Z., Cole C.D., Barabas A.D., Barabas A.N., and Lafreniere R. Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 13 (2006) 17-24
7. Grabar P. The problem of auto-antibodies; an approach to a theory. Tex Rep Biol Med 15 (1957) 1-16
8. Weir D.M., and Pinckard R.N. Failure to induce tolerance to rat tissue antigens. Immunology 13 (1967) 373-380
9. Weir D.M., and Elson C.J. Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 12 (1969) 254-260
10. Weir D.M. Altered antigens and autoimmunity. Vox Sang 16 (1969) 304-313
11. Barabas A.Z., Elson C.J., and Weir D.M. The serology of autologous immune complex nephritis in the rat. Clin Exp Immunol 4 (1969) 345-351
12. Solvason N., Chen X., Shu F., and Kearney J.F. The fetal omentum in mice and humans. A site enriched for precursors of CD5 B cells early in development. Ann N Y Acad Sci 651 (1992) 10-20
13. Manz R.A., Arce S., Cassese G., Hauser A.E., Hiepe F., and Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14 (2002) 517-521
14. Ebringer A., Thorpe C., Pirt J., Wilson C., Cunningham P., and Ettelaie C. Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens?. Environ Health Perspect 105 (1997) 1172-1174
15. Harel M., and Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality?. Ann N Y Acad Sci 1069 (2006) 322-345
16. Orbach H., and Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6 (2007) 261-266
17. Conti F., Rezai S., and Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 8 (2008) 124-128
18. Selmi C., Battezzati P.M., Gershwin M.E., Tishler M., and Shoenfeld Y. Vaccines in the 21st century: the genetic response and the innocent bystander. Autoimmun Rev 4 (2005) 79-81
19. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82 (2004) 488-496
20. Berinstein N.L. Enhancing cancer vaccines with immunomodulators. Vaccine 25 Suppl 2 (2007) B72-B88
21. Lollini P.L., and Forni G. Antitumor vaccines: is it possible to prevent a tumor?. Cancer Immunol Immunother 51 (2002) 409-416
22. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 29 (2002) 30-35
23. Maloney D.G., Smith B., and Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 29 (2002) 2-9
24. Perosa F., Favoino E., Caragnano M.A., Prete M., and Dammacco F. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev 4 (2005) 526-531
25. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 18 (1997) 335-343
26. Faria A.M., and Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 73 (1999) 153-264
27. Fox R.J., and Ransohoff R.M. New directions in MS therapeutics: vehicles of hope. Trends Immunol 25 (2004) 632-636
28. Peakman M., and Dayan C.M. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?. Immunology 104 (2001) 361-366
29. Barabas A.Z., Cole C.D., Barabas A.D., Bahlis N.J., and Lafreniere R. A vaccination technique to combat presently untreatable chronic ailments. BioProcessing Journal 6 (2007) 12-18
30. Liu Q., Kriksunov I.A., Graeff R., Munshi C., Lee H.C., and Hao Q. Crystal structure of human CD38 extracellular domain. Structure 13 (2005) 1331-1339
31. Munshi C.B., Fryxell K.B., Lee H.C., and Branton W.D. Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol 280 (1997) 318-330
32. Rammensee H.G., Weinschenk T., Gouttefangeas C., and Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 188 (2002) 164-176
33. Barabas A.Z., Cole C.D., Barabas A.D., and Lafreniere R. Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 85 (2004) 277-285
34. Barabas A.Z., Cole C.D., Barabas A.D., and Lafreniere R. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 56 (2006) 181-190
35. Barabas A.Z., Cole C.D., Barabas A.D., and Lafreniere R. Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics: Targets & Therapy 1 (2007) 59-68
36. Barabas A.Z., Cole C.D., Barabas A.D., Bahlis N.J., and Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs 11 (2008) 111-115
37. Casali P., and Notkins A.L. CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 10 (1989) 364-368
38. Chen Z.J., Wheeler J., and Notkins A.L. Antigen-binding B cells and polyreactive antibodies. Eur J Immunol 25 (1995) 579-586
39. Barabas A.Z., Cole C.D., Barabas A.D., Cowan J.M., Yoon C.S., Waisman D.M., et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 85 (2004) 201-212
40. Elson C.J., and Weir D.M. Chemotaxis of polymorphs induced by tissue antigens and normal serum in rats: a possible clearance mechanism. Clin Exp Immunol 2 (1967) 581-588